XM does not provide services to residents of the United States of America.
R
R

Resmed

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Australia shares slump more than 3% as US recession worries trigger sell-off

Australia shares slump more than 3% as US recession worries trigger sell-off ASX 200 posts worst session since June 2022 ASX volatility index at more than 2-year high Tech stocks lose 6.6%, financials drop 5% RBA policy decision due on Tuesday Updates to close By Himanshi Akhand and Rajasik Mukherjee Aug 5 (Reuters) - Australian shares slumped more than 3% in their worst trading session in over two years on Monday, joining a global sell-off in riskier assets after weak U.S.
A
R

Australia-listed shares of ResMed climb to 1-year high as analysts hike PT

BUZZ-Australia-listed shares of ResMed climb to 1-year high as analysts hike PT ** ASX-listed shares of ResMed RMD.AX RMD.N rise as much as 7% to A$34.020, their highest since Aug 2, 2023 ** Analysts at J.P. Morgan lift their price target on the medical equipment maker to A$37 from A$34.5 after its quarterly results ** Macquarie analysts raise PT to A$36.25 from A$35.40 ** U.S.-based co on Friday reported adj.
R

Resmed Inc reports results for the quarter ended in January - Earnings Summary

Resmed Inc reports results for the quarter ended in January - Earnings Summary Resmed Inc RMD.N reported quarterly adjusted earnings of $2.08​​ per share for the quarter ended in January, higher than the same quarter last year, when the company reported EPS of $1.60. The mean expectation of twelve analysts for the quarter was for earnings of $2.07 per share.
R

Resmed Inc reports results for the quarter ended in June - Earnings Summary

Resmed Inc reports results for the quarter ended in June - Earnings Summary Resmed Inc RMD.N reported quarterly adjusted earnings of $2.08​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $1.60. The mean expectation of twelve analysts for the quarter was for earnings of $2.07 per share.
R

ResMed meets estimates on steady demand for its sleep apnea devices

ResMed meets estimates on steady demand for its sleep apnea devices Aug 1 (Reuters) - Medical equipment maker ResMed RMD.N reported fourth-quarter revenue in line with estimates on Thursday, on steady demand for its sleep apnea treatment devices. The company's quarterly revenue rose 9% to $1.22 billion, in line with estimates of $1.22 billion. ResMed makes ventilators and machines that provide continuous and bilateral positive airway pressure, known as CPAP and BIPAP, which are used for non-inva
R

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.